Verastem (VSTM) to Release Quarterly Earnings on Thursday

Verastem (NASDAQ:VSTM) will likely be releasing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Verastem to post earnings of ($0.46) per share and revenue of $22.8790 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Verastem Price Performance

VSTM stock opened at $5.86 on Tuesday. Verastem has a one year low of $3.43 and a one year high of $11.24. The company’s fifty day moving average price is $4.72 and its 200-day moving average price is $5.39. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.00 and a current ratio of 3.04. The company has a market capitalization of $514.77 million, a PE ratio of -2.17 and a beta of 0.29.

Analyst Ratings Changes

Several equities analysts recently weighed in on VSTM shares. BTIG Research reaffirmed a “buy” rating and set a $18.00 target price on shares of Verastem in a research note on Thursday, July 2nd. Royal Bank Of Canada set a $14.00 price target on shares of Verastem and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Mizuho cut their price objective on Verastem from $16.00 to $14.00 and set an “outperform” rating for the company in a research report on Thursday, May 14th. Jefferies Financial Group cut their price objective on Verastem from $15.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, June 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Verastem in a report on Wednesday, June 24th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Verastem currently has an average rating of “Moderate Buy” and an average target price of $14.40.

Insider Buying and Selling at Verastem

In related news, CEO Dan Paterson sold 20,871 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $4.18, for a total value of $87,240.78. Following the sale, the chief executive officer owned 591,242 shares in the company, valued at approximately $2,471,391.56. The trade was a 3.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.94% of the company’s stock.

Hedge Funds Weigh In On Verastem

Several institutional investors have recently bought and sold shares of the business. Osaic Holdings Inc. raised its position in shares of Verastem by 27.1% during the 4th quarter. Osaic Holdings Inc. now owns 20,476 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 4,366 shares in the last quarter. Graham Capital Management L.P. purchased a new position in Verastem in the fourth quarter worth about $181,000. Entropy Technologies LP bought a new stake in Verastem during the fourth quarter worth approximately $161,000. Quarry LP bought a new stake in Verastem during the fourth quarter worth approximately $208,000. Finally, MetLife Investment Management LLC raised its position in Verastem by 10.6% during the fourth quarter. MetLife Investment Management LLC now owns 28,929 shares of the biopharmaceutical company’s stock valued at $223,000 after purchasing an additional 2,784 shares during the period. Institutional investors own 88.37% of the company’s stock.

Verastem Company Profile

Verastem Oncology, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.

The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S.